Barclays
ZVSA

Barclays’s ZyVersa Therapeutics ZVSA Stock Holding History

Barclays’s Portfolio ZVSA Stock Details ZVSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3
Closed -$270 – 4728
2023
Q2 		$270 Buy
+3
New +$787 ﹤0.01% 4411
2022
Q4 		– Sell
-396
Closed -$1.39M – 5399
2022
Q3 		$1.39M Hold
396
– – ﹤0.01% 1991
2022
Q2 		$1.38M Buy
+396
New +$1.38M ﹤0.01% 2120

Other funds holding ZVSA

Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
WAG
Winthrop Advisory Group Boston, Massachusetts $1.48B AUM 22.62% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Barclays's ZVSA Position: Q3 2023 in Review

Barclays sold out of ZyVersa Therapeutics (ZVSA) in Q3 2023, closing a stake of 3 shares — an estimated $270 sold.

Barclays first reported a position in ZVSA in Q2 2022 and held it in 3 quarters. The position peaked at $1.39M in Q3 2022. 9 funds tracked by Wall St. Rank hold ZVSA as of Q3 2023.

  • Barclays reported no remaining ZyVersa Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Barclays sold 3 ZyVersa Therapeutics shares in Q3 2023, an estimated $270.
  • Barclays first reported a position in ZyVersa Therapeutics in Q2 2022 and held it in 3 quarters.
  • Barclays's ZyVersa Therapeutics position peaked at $1.39M in Q3 2022.
  • 9 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q3 2023.

Based on Barclays's 13F filing for Q3 2023, filed 7 Nov 2023.